![]() We evaluated the effects of darbepoetin alfa on clinical outcomes in patients with systolic heart failure and anemia. We evaluated the effects of darbepoetin alfa on clinical outcomes in patients with systolic heart failure and anemia.Patients with systolic heart failure and anemia have worse symptoms, functional capacity, and outcomes than those without anemia. Patients with systolic heart failure and anemia have worse symptoms, functional capacity, and outcomes than those without anemia. Swedberg, Karl Young, James B Anand, Inder S Treatment of anemia with darbepoetin alfa in systolic heart failure The aim of the present analysis was to evaluate the efficacy and tolerability of an every-2-week (Q2W) schedule of darbepoetin alfa. Mann, J Kessler, M Villa, Giulio PalludanĪIM: Darbepoetin alfa has a longer half-life than epoetin-(EPO) alfa or beta, allowing administration at less frequent intervals for the treatment of renal anemia. assigned to darbepoetin alfa and 496 patients assigned to placebo (Pchronic kidney disease.ĭarbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients METHODS: In this study involving 4038 patients with diabetes, chronic kidney disease, and anemia, we randomly assigned 2012 patients to darbepoetin alfa to achieve a hemoglobin level of approximately 13 g per deciliter and 2026 patients to placebo, with rescue darbepoetin alfa when the hemoglobin. Although darbepoetin alfa can effectively increase hemoglobin levels, its effect on clinical outcomes in these patients has not been adequately. Pfeffer, Marc A Burdmann, Emmanuel A Chen, Chao-YinīACKGROUND: Anemia is associated with an increased risk of cardiovascular and renal events among patients with type 2 diabetes and chronic kidney disease. We sought to identify baseline characteristics and postrandomization factors that might explain this association.Ī trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease More strokes were observed in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) among patients assigned to darbepoetin alfa. Skali, Hicham Parving, Hans-Henrik Parfrey, Patrick S As of today, we know of many vitamin D metabolites and have developed the techniques to measure most of them how ever, many questions remain concerning their physiological role.Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa Assays for the other metabolites, in particular, 1,25-dihydroxyvitamin D, were described even more recently. Assays to measure the major cir culating form of vitamin D, 25-hydroxyvitamin D, were described 10 years ago. This has had profound implications in our understanding of a variety of metabolic bone, kidney, and gastrointestinal diseases. The knowledge that vitamin D must be metabolized to produce its biologic effects is only 15 years old. As the sensitivity of the calcitonin radioimmunoassay has improved, our understanding of the role of calcitonin in normal physiological processes has increased. diagnosis of a previously poorly understood cancer, medullary carcinoma of the thyroid, frequently associated with the familial multiple endo crine neoplasia type 2 syndromes (a and b). The calcitonin (CT) radioimmunoassay came later and achieved rapid success in the. Sensitive parathyroid hormone (PTH) radioimmunoassays appeared in the early 1970s, and with them came a whole new appreciation for the prevalence and implications of hyperparathyroidism, primary or secondary, in the popu lation. Techniques for such measurements have only been available for the past 10 years or so and remain in a state of rapid development. The ability to measure accurately the hormones regulating calcium homeosta sis is the fundamental first step toward understanding the roles these hormones play in health and disease.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |